SOMERSET, N.J., August 22, 2007 /PRNewswire-FirstCall/ -
Alfacell Corporation today announced that a paper published in the
International Journal of Oncology (2007; Vol. 31, Issue 3: 663-669)
reports that ONCONASE(R) substantially decreases reactive oxygen
intermediates (ROI) in normal cell types and tumor cell lines. The
observed antioxidant activity of ONCONASE may be important to its
cytotoxic effect on cancer cells and mechanistic synergism with
other anti-cancer agents.

The pre-clinical in vitro research conducted by Alfacell and
researchers at New York Medical College demonstrated that treatment
of cells in cultures with ONCONASE reduced intracellular oxidative
stress by suppressing ROI generation and promoting their
degradation. The anti-oxidative function of ONCONASE may be an
important element of its antiproliferative/cytotoxic activity
towards cancer cells and a possible mechanism of its
well-documented synergism with other anti-cancer agents.
Additionally, the data indicate that ONCONASE has a propensity to
reverse the generation of ROI from asbestos exposure in mesothelial
cells. The Company is currently conducting a Phase IIIb human
clinical trial of ONCONASE for the treatment of patients suffering
from unresectable malignant mesothelioma.

"The data further confirm the cytotoxic effect of ONCONASE on
cancer cells," said Kuslima Shogen, Alfacell's chairman and chief
executive officer. "ONCONASE's therapeutic potential is broad. This
study shows that ONCONASE has potential not only for cancer, but
for conditions pathogenetically related to oxidative stress or the
activation of NF-kappa B, such as inflammation, autoimmune
diseases, atherosclerosis and septic shock."

About ONCONASE(R)

ONCONASE is a first-in-class product candidate based on
Alfacell's proprietary ribonuclease (RNase) technology. A natural
protein isolated from the leopard frog, ONCONASE has been shown in
the laboratory and clinic to target cancer cells while sparing
normal cells. ONCONASE triggers apoptosis, the natural death of
cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a
biopharmaceutical product candidate that works in a manner similar
to RNA interference (RNAi) through late-stage clinical trials. The
product candidate, ONCONASE, is an RNase that overcomes the
challenges of targeting RNA for therapeutic purposes while enabling
the development of a new class of targeted therapies for cancer and
other life-threatening diseases. In addition to an ongoing Phase
IIIb study in malignant mesothelioma, Alfacell is conducting a
Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC)
and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute
"forward- looking" statements, usually containing the words
"believe," "estimate," "project," "expect" or similar expressions.
Forward-looking statements involve risks and uncertainties that
could cause actual results to differ materially from the
forward-looking statements. Factors that would cause or contribute
to such differences include, but are not limited to, uncertainties
involved in transitioning from concept to product, uncertainties
involving the ability of the company to finance research and
development activities, potential challenges to or violations of
patents, uncertainties regarding the outcome of clinical trials,
the company's ability to secure necessary approvals from regulatory
agencies, dependence upon third-party vendors, and other risks
discussed in the company's periodic filings with the Securities and
Exchange Commission. By making these forward-looking statements,
the company undertakes no obligation to update these statements for
revisions or changes after the date of this release.